Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$29.15 USD

29.15
263,087

-0.08 (-0.27%)

Updated Nov 13, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

by Zacks Equity Research

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

Alkermes Sinks as FDA Refuses to Approve Depression Drug

by Zacks Equity Research

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

What Makes Alkermes (ALKS) a New Buy Stock

by Zacks Equity Research

Alkermes (ALKS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CBM or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CBM vs. ALKS: Which Stock Is the Better Value Option?

Biogen Begins Improved Dosing Regimen on Tysabri in Phase III

by Zacks Equity Research

Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.

    Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug

    by Zacks Equity Research

    Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.

    Alkermes (ALKS) Down 14.2% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View

    by Zacks Equity Research

    Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.

    Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook

    by Zacks Equity Research

    Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.

    Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    Alkermes (ALKS) delivered earnings and revenue surprises of 216.67% and 5.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?

    by Zacks Equity Research

    We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.

    Alkermes Boasts Strong Portfolio and Impressive Pipeline

    by Zacks Equity Research

    Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

      EBS or ALKS: Which Is the Better Value Stock Right Now?

      by Zacks Equity Research

      EBS vs. ALKS: Which Stock Is the Better Value Option?

      FDA Sets Action Date for Recro's Pain Management Candidate

      by Zacks Equity Research

      The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

        VistaGen Up on Fast Track Designation to Pain Candidate

        by Zacks Equity Research

        VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.

          Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

          by Zacks Equity Research

          FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

            Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

            by Zacks Equity Research

            Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

              Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo

              by Zacks Equity Research

              Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.

                ANIK vs. ALKS: Which Stock Is the Better Value Option?

                by Zacks Equity Research

                ANIK vs. ALKS: Which Stock Is the Better Value Option?

                  What's in Store for Universal Health's (UHS) Q2 Earnings?

                  by Zacks Equity Research

                  Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.

                    What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?

                    by Zacks Equity Research

                    HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.

                      Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?

                      by Zacks Equity Research

                      Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.

                        Alkermes' Aristada Initio Approved by FDA for Schizophrenia

                        by Zacks Equity Research

                        FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.

                          Company News For Jul 3, 2018

                          by Zacks Equity Research

                          Companies in the news are: CLB, ALKS, ACXM and URI

                            Key FDA Events in June Investors Need to Watch Out For

                            by Zacks Equity Research

                            Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.